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A mutation at nucleotide 1896 (G1896A) is the most common cause for the loss of HBeAg. In contrast to
clinical data, cell culture studies report a high-replicating phenotype for the G1896A mutant. Differences
between the wild-type and the G1896A mutant in early steps of HBV replication including the synthesis
of pre-genomic RNA and transcripts have not been investigated. The G1896A mutant is associated with
higher replication ﬁtness, transcription efﬁciency and higher levels of secreted HBsAg than the wild-
type. Interestingly, trans-complementation of the G1896A mutant with HBeAg lowers the replication
ﬁtness and transcriptionefﬁciency to levels comparable to that of the wild-type. Our results highlight the
role of HBeAg in modulating the early steps in HBV replication. In sum, our ﬁndings highlight the role of
HBeAg in regulating hepatitis B virus replication ﬁtness and transcription efﬁciency and new insights on
the early steps of replication in the G1896A mutant.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Hepatitis B virus (HBV) remains a major problem world-wide
despite the availability of an efﬁcacious vaccine. Chronic HBV
infection is associated with a spectrum of manifestations including
ﬁbrosis, cirrhosis and hepatocellular carcinoma. Hepatitis B e
antigen (HBeAg), a secreted protein encoded by the preC/C ORF
is dispensable for HBV replication in vitro (Tong et al., 1991), but is
required to establish persistent infection in vivo (Chen et al., 1992).
An association between the presence of HBeAg and high virus
loads was ﬁrst reported in the 1980s (Chu et al., 1985); in the last
3 decades several epidemiological studies from across the globe have
conﬁrmed the link between HBeAg and high virus loads (Lindh et al.,
1999; Chu et al., 2003; Mendy et al., 2008). However, the biological
role of HBeAg still remains a mystery. It remains unknown how
HBeAg modulates HBV replication. Seroconversion of HBeAg to its
corresponding anti-HBe antibody during the course of chronic
hepatitis B (CHB) often correlates with immune selection of HBV
variants expressing little or no HBeAg (Carman et al., 1989; Okamoto
et al., 1990; Brunetto et al., 1991). Majority of individuals with HBeAg-
negative CHB remain in inactive carrier state, although a small
proportion (15–40%) may potentially develop severe and progressive
form of liver disease.
The most common and clinically relevant mutation associated
with HBeAg-negative HBV infection is a G to A substitution at
nucleotide 1896 (resulting in a stop codon) in HBV genome leading
to abrogation of HBeAg synthesis (Laras et al., 1998). The precore
STOP codon variant G1896A is detected in upto 92% of HBeAg-
negative chronic carriers (Funk et al., 2002). The G1896A variant is
associated with lower HBV replication levels and better outcome
(Liaw, 2009; Yang et al., 2008; Lindh et al., 1999) but in vitro studies
have failed to demonstrate reduced replication competence of this
variant (Chen et al., 2003; Jammeh et al., 2008). In contrast to clinical
ﬁndings, previous in vitro studies have demonstrated a high replica-
tion phenotype for the G1896A mutant when compared to the wild
type (Lamberts et al., 1993; Scaglioni et al., 1997a, 1997b; Inoue et al.,
2011). A few reports showed no major difference in the replication of
G1896A mutant and the wild-type in vitro (Tong et al., 1992; Chen et
al., 2003). The contrasting results obtained in vitro and in vivo, still
remain a conundrum. In addition, studies investigating the biological
role of HBeAg have demonstrated HBeAg-mediated inhibition of HBV
pre-genomic (pg) RNA encapsidation (Scaglioni et al., 1997a) leading
to reduced HBV DNA synthesis (Scaglioni et al., 1997a; Lamberts et al.,
1993). Nonetheless, it remains unknown if HBeAg alters the efﬁ-
ciency of HBV pg-RNA and HBV pre-core RNA synthesis.
The HBV constructs used in previous studies and key ﬁndings
are summarized in Table 1. Most studies investigating the role of
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G1896A in cell culture have used more than unit-length HBV
constructs (Table 1). The pitfalls of using more than unit-length
constructs are generally overlooked. For example, in the 1.3x HBV
constructs, the complete HBV x protein open reading frame and
the enhancer I/II regions are duplicated (Delaney and Isom, 1998).
The duplication of regulatory elements and the use of hetero-
logous promoters (eg. CMV promoters) in these constructs con-
stitutes an extremely robust system for HBV replication; however
it is possible that the robustness may mask the differences, if any,
between the constructs studied. We therefore believe that the use
of these 1.3x constructs may not be ideal to study differences in
HBV replication.
In this study we use unit-length monomeric constructs without
heterologous promoters to study the replication of the G1896A
mutant in cell culture. In addition, we also investigate the role of
HBeAg in HBV replication by trans-complementation of HBeAg in
cells transiently transfected with the full-length G1896A construct
to elucidate the role of HBeAg, if any in modulating the synthesis
of HBV pg-RNA and HBV pre-core RNA. We believe that the
ﬁndings reported in this study highlight yet unknown biological
functions of HBeAg in modulating HBV replication ﬁtness and
transcription efﬁciency, albeit unable to resolve the differences
between in vitro and in vivo data using unit-length constructs.
Methods
Creation of constructs
The complete HBV genome from an HBeAg positive individual
infected with genotype D was ampliﬁed using methods described
previously with primers containing BspQI (an isoschizomer of SapI)
restriction sites (Gunther et al., 1995). The full-length HBV genome
was cloned into pSC-A vector (Strataclone PCR cloning kit, Agilent
Technologies) to create unit-length wild-type construct (wt-HBV).
Using the wild-type clone as the template, G1896A mutant unit-
length construct (G1896A-HBV) was created using appropriate
primers (Table 2), ampliﬁed and cloned similarly as described for
the wild-type. These clones were then sequenced to ensure
absence of mutations in the genome which might inﬂuence HBV
replication. The wt-HBV and the G1896A-HBV constructs had
identical sequences, except at nucleotide position 1896.
For trans-complementation experiments we created a
pCMVHBeAg construct in which the pre-C/core ORF (this ORF
encodes both HBeAg and HBV core antigen) was cloned into
mammalian expression vector (pEGFP-n1) with a CMV promoter.
We also created a pCMVG1896A construct expressing pre-C/core
ORF with the G1896A mutation (results in a premature stop codon
Table 1
Summary of cell culture methods used to study replication behavior of wild type HBV and its corresponding G1896A mutant.
Serial
number
Construct
used
Key ﬁndings Secreted
HBsAg
Virion
secretion
Replication ﬁtness/Transcription
efﬁciency
References
1 1.3X G1896A4Wt (HBV DNA levels in culture
supernatant)
Not studied Not studied Not studied Inoue et al., 2011
2 1.2X G1896A4Wt (Encapsidated RNA and core
associated DNA)
G1896A¼Wt Not studied Not studied Scaglioni et al.,
1997b
3 Baculovirus-
HBV
G1896A4Wt (Replicative intermediates) Not studied Not studied Not studied Heipertz et al.,
2007
4 1.2X G1896A¼Wt (Replicative intermediates) Not studied G1896A¼Wt Not studied Tong et al., 1992
5 1.2X G1896A 4Wt (Replicative intermediates) Not studied Not studied Not studied Lamberts et al.,
1993
6 1.2X G1896A 4Wt (Core-associated DNA) G1896A¼Wt Not studied Not studied Scaglioni et al.,
1997a
7 1.3X G1896A¼Wt (Replicative intermediates) Not studied Not studied Not studied Inoue et al., 2009
8 1.3X G1896A¼Wt (Intracellular DNA levels) Not studied G1896A¼Wt Not studied Chen et al., 2003
9 1.2X G1896AoWt (Precore-RNA levels) Not studied G1896A¼Wt Not studied Jammeh et al.,
2008
Table 2
Primers and probe used in the study.
Primer Sequence (50 to 30) References
P1 CCGGAAAGCTTGAGCTCTTCTTTTTCACCTCTGCCTAATCA Gunther et al., 1995
P2 CCGGAAAGCTTGAGCTCTTCAAAAAGTTGCATGGTGCTGG Gunther et al., 1995
G1896A-HBV F CCGGAAAGCTTGAGCTCTTCTTAGGGCATGGACATTGACC Designed in-house
G1896A-HBV R CCGGAAAGCTTGAGCTCTTCCCTAAAGCCACCCAAGGCAC Designed in-house
PGP CACCTCTGCCTAATCATC Laras et al., 2006
PCP GGTCTGCGCACCAGCACC Laras et al., 2006
BC1 GGAAAGAAGTCAGAAGGCAA Laras et al., 2006
CCC F GTGCCTTCTCATCTGCCGG Laras et al., 2006
CCC R GAACTTTAGGCCCATATTAGTG Designed in-house
CCC Probe FAM-TTCAAGCCTCCAAGCTGTGCCTTGGGTGGC-TAMRA Mazet-Wagner et al., 2006
GAPDH F TGCACCACCAACTGCTTAGC Li et al., 2012
GAPDH R GGCATGGACTGTGGTCATGAG Li et al., 2012
HBV S F CCTATGGGAGTGGGCCTCA Vivekanandan et al., 2009
HBV S R CCCCAATACCACATCATCCATATA Vivekanandan et al., 2009
PGP-gene speciﬁc cDNA (cPgp) TTTCCCACCTTATGAGTCCA Designed in-house
pCMVHBeAg F CCGGACTCGAGATGCAACTTTTTCACCTCTGCC Designed in-house
pCMVHBeAg R CCGGAGGATCCCTAACATTGAGATTCCCGAG Designed in-house
pCMVG1896A F CCGGACTCGAGATGCAACTTTTTCACCTCTGCC Designed in-house
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and hence this construct is incapable of HBeAg synthesis) to serve
as a control plasmid for trans-complementation experiments.
Transfection
The Huh7 human hepatoma cells were cultured in Dulbecco's
modiﬁed eagle medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 5000 U/ml penicillin and 5000 mg/ml Strep-
tomycin maintained at 37 1C with 5% CO2. Huh7 cells were seeded
at a density of 4105 cells per well in a standard 24-well culture
plate and were transfected with the wt-HBV and G1896A-HBV
constructs separately into each well. The unit-length monomeric
constructs of wt-HBV and G1896A-HBV were released from the
vectors following digestion with BspQI and were gel-puriﬁed using
column-based puriﬁcation method (QIAquick Gel Extraction Kit,
Qiagen). The constructs were quantitated using real-time PCR with
primers targeting the surface gene of HBV genome. Each well was
transfected with 10–11 log copies of each construct using lipofec-
tamine 2000 (Invitrogen). Once inside the cells, the linear con-
structs having sticky ends are repaired by host DNA repair
enzymes resulting in the formation of HBV covalently closed
circular (ccc) DNA form which serves as the template for all HBV
RNA transcripts and HBV pre-genomic RNA (pg-RNA). The cells
and supernatant were harvested at 3 days post-transfection.
Assessment of replication ﬁtness and transcription efﬁciency
Cells were trypsinized and resuspended in PBS (phosphate
buffered saline) for DNA extraction. The QIAamp DNA mini kit
(Qiagen) was used to extract DNA as per the manufacturer's
instructions. Total RNA was extracted using 1 ml of TRIzol (Invi-
trogen) as per the manufacturer's instructions. The RNA pellet was
dissolved in nuclease-free water (Qiagen). cDNA was synthesized
from 1 mg of DNase I treated RNA using the iScript cDNA synthesis
Kit (Biorad) using random primers. Primers speciﬁcally targeting
pre-core HBV transcripts and HBV pre-genomic RNA were used for
real-time PCR quantitation of the respective targets (Table 2)
(Laras et al., 2006) using SsoFast Evagreen Supermix (Biorad).
GAPDH mRNA levels determined using real-time PCR were used to
normalize HBV RNA levels. HBV covalently closed circular (ccc)
DNA was quantitated by real-time quantitative PCR with a premix
Ex Taq (probe qPCR, TakaRa) master mix using appropriate
primers and a taqman probe (Mazet-Wagner et al., 2006;
Table 2). Standard curves were generated for all real-time PCR
assays using serial dilutions of the appropriate clones to facilitate
absolute quantitation.
Replication ﬁtness is an important parameter for assessing the
replication capacity of a given HBV strain. This is measured as the
number of pre-genomic HBV RNA transcripts made per HBV ccc
DNA (pgRNA/ccc DNA) (Laras et al., 2006). The number of precore
RNA transcripts produced per HBV ccc DNA inside the cell (precore
RNA/HBV ccc) is used to assess the transcription efﬁciency of HBV
(Laras et al., 2006).
Estimation of secreted HBV proteins
Culture supernatants were tested for HBsAg levels using
commercially available HBsAg (MONOLISA, BioRad) ELISA Kits as
per the manufacturer's instructions. The samples were diluted
appropriately to ensure that the OD values were within the linear
range of the assay.
Analysis of virion secretion
Estimation of virions secreted in the supernatant usually
requires a large volume of supernatant. We have optimized an
assay in which virions are immunocaptured followed by real-time
PCR for estimation of virion-associated DNA (Samal et al., 2015).
This assay allows estimation of virions in small quantities of
supernatant (Samal et al., 2015). Brieﬂy, 150 mL of the supernatant
was added to a commercially available monoclonal anti-HBs
coated ELISA plate (Bio-Rad) for immunocapture of virions fol-
lowed by DNA extraction using the QIAamp DNA mini kit (Qiagen)
and quantitation using real time PCR as described earlier (Samal et
al., 2015).
Trans-complementation experiments:
To understand the role of HBeAg in modulating HBV replication
we performed trans-complementation experiments. The G1896A-
HBV construct was co-transfected with 0.3 mg of pCMVHBeAg
(HBeAg expressing) or pCMVG1896A (contains a pre-mature stop
codon, does not express HBeAg; serves as a control) into Huh7
cells as described above. All transfections were done in triplicate.
Cells and supernatant were harvested 3 days post-transfection for
DNA, RNA and protein analyses.
For trans-complementation experiments the transcription efﬁ-
ciency and secreted HBV proteins were estimated as described
above. The pre-core/core ORF mRNA encoded by pCMVHBeAg or
pCMVG1896A contains the regions that will be ampliﬁed by the
primers used for estimation of HBV-pg RNA. Estimation of full-
length construct derived HBV-pg RNA is critical to assess the
impact of trans-complemented HBeAg on replication ﬁtness of
HBV. For this purpose cDNA synthesis was done using a HBV
primer (cPgp primer) that will bind to full-length HBV encoded
HBV-pg RNA but not to the pCMVHBeAg- or pCMVG1896A-
encoded HBV RNA. In addition to the cPgp primer, a gene speciﬁc
primer (GAPDH R) for GAPDH was also included for cDNA synth-
esis. Therefore we were able to speciﬁcally estimate full-length
HBV derived HBV-pg RNA using real time PCR and normalization
was done using GAPDH levels.
Results and Discussion
G1896A-HBV has higher replication ﬁtness and transcription
efﬁciency than wt-HBV
Interestingly, the G1896A-HBV construct showed 1.5 fold higher
replication ﬁtness (HBV pg-RNA/cccDNA) than the wt-HBV construct
(Po0.05; Fig. 1A). In addition, the G1896A-HBV construct showed
2.0 fold higher transcription efﬁciency (HBV pre-coreRNA/cccDNA)
than the wild-type construct (Po0.05; Fig. 1B). These ﬁndings have
noteworthy implications to our current understanding of the replica-
tion characteristics of this common HBeAg negative mutant. Previous
in vitro studies have reported a high-replicating phenotype for
G1896A mutant than the wild-type HBV (Lamberts et al., 1993;
Scaglioni et al., 1997a,; 1997b) based on detection of higher levels of
DNA replicative intermediates in the G1896 mutant. Higher rates of
HBV-pg RNA encapsidation by the G1896A mutant is believed to
increase HBV DNA synthesis within the nucleocapsids (Lamberts et
al., 1993). However, the replication ﬁtness (efﬁciency of HBV pg-RNA
synthesis) and transcription efﬁciency (efﬁciency of HBV pre-core
RNA synthesis) of the G1896A mutant have not been studied before.
Our ﬁndings of higher replication ﬁtness and transcription efﬁciency
of the G1896A mutant than the wild-type imply that increased HBV
DNA synthesis reported for this mutant may not be fully explained by
higher encapsidation rates of HBV-pg RNA as perceived earlier.
Higher efﬁciency of HBV pg-RNA and HBV pre-core RNA synthesis
by the G1896A mutant represents a novel perspective that explains,
at least in part the high-replicating phenotype observed for this
mutant.
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We were not able to resolve the differences between in vitro and
in vivo data for the G1896A mutant. Transient transfections in cell
culture models may not accurately reﬂect HBV replication in chroni-
cally HBV-infected individuals; unlike in transient transfection sys-
tems, cccDNA may persist for long periods in time in hepatocytes of
infected individuals. It is possible that a key host factor modulating the
biological role of HBeAg is lost due to genetic/epigenetic changes in
HCC (Dannenberg and Edenberg, 2006; Meng et al., 2007; Taniguchi et
al., 2002). Most cell culture studies use HCC cells lines Huh7 or HepG2
cells; it is therefore possible that the observed differences between
in vitro and in vivo data may be masked due to the genetic/epigenetic
changes in these cell lines. This explanation, although speculative, is
partially supported by lower virus loads in patients with HBV-related
HCC than in chronic HBV patients with cirrhosis (Mendy et al., 2010).
G1896A-HBV produces more HBsAg than the wt-HBV
The HBsAg secreted in the culture supernatant of the cells
transfected with wt-HBV or the G1896A-HBV was estimated using
MONOLISA HBsAg ELISA kit. Interestingly, higher levels of secreted
HBsAg were detected in the cells transfected with the G1896A-
HBV mutant than those transfected with the wt-HBV (P¼0.008:
Fig. 2A). This ﬁnding is in keeping with higher transcription
efﬁciency for the G1896A-HBV mutant than that of the wt-HBV.
Two previous studies found no signiﬁcant differences in secreted
HBsAg levels between the wild-type and the G1896A mutant
(Jammeh et al., 2008; Scaglioni et al., 1997b). Both the studies
used more than unit-length constructs of HBV in which the X
region (encoding HBx protein, a transcription activator) and the
enhancer II region are duplicated. It is possible that the duplication
of regulatory elements may lead to robust transcription that may
have masked the differences in HBsAg levels, if any, between the
wild-type and its corresponding G1896A mutant. In addition, one
of the studies used a genotype C construct (Jammeh et al., 2008).
Genotype C strains may contain a cytosine at nucleotide position
1858 (as opposed to a thymine at this position in genotypes B,D
and E (Alestig et al., 2001). In HBV RNA the 1896 nucleotide base
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Fig. 1. (A) Replication ﬁtness: G1896A-HBV mutant has higher replication ﬁtness
(pregenomic RNA/cccDNA) than the corresponding wt-HBV (P¼0.006)
(B) Transcription efﬁciency: G1896A-HBV mutant has higher transcription efﬁ-
ciency (precore RNA/cccDNA) than the corresponding wt-HBV (Po0.005).
0
0.1
0.2
0.3
0.4
0.5
0.6
Wt G1896A
H
B
sA
g 
O
D
 (4
50
nm
)
P =0.008
1
10
100
1000
10000
100000
1000000
Wt G1896A
V
iri
on
s s
ec
re
te
d/
m
l o
f s
up
er
na
ta
nt
P =0.15
Fig. 2. (A) Detection of HBsAg levels (OD values at 450 nm) in culture supernatant
of cells transfected with wt-HBV construct and its corresponding G1896A-HBV. The
supernatants were harvested 72 h post-transfection and tested at dilution of 1:30.
Precore G1896A mutant showed increased HBsAg levels than the wild-type
construct (P¼0.008) (B) Quantitative estimation of secreted hepatitis B virions in
cell culture supernatant: secreted hepatitis B virions were estimated in undiluted
supernatants of cells transfected with wild-type HBV construct and the G1896A
mutant. The differences in virion secretion between the G1896A and the wild-type
were not signiﬁcant (P40.05).
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pairs with the 1858 nucleotide in stem loop structure (Pollack and
Ganem, 1993; Lindh et al., 1997) and compatibility between the
nucleotides at 1858 and 1896 inﬂuence the selection of the
G1896A mutation (Vivekanandan et al., 2008). Therefore a G to A
substitution at nt.1896 will result in wobble pairing (A:C) if the
genotype C strain used contained a cytosine at nucleotide position
1858; this may have signiﬁcant impact on the replication of the
G1896 mutant created using site-directed mutagenesis.
In this study, we report a correlation between the G1896A
mutant and higher HBsAg levels. This ﬁnding is in keeping with
almost 2 fold higher HBsAg/HBV DNA ratios among HBeAg
negative individuals than HBeAg positive cases (Jaroszewicz
et al., 2010; Liaw, 2011), indicating more efﬁcient HBsAg synthesis
in HBeAg negative individuals.
No signiﬁcant difference in virion secretion
Despite the higher replication ﬁtness and transcription efﬁ-
ciency of the G1896A-HBV, there were no signiﬁcant differences
between the wt-HBV and the G1896A-HBV in virion secretion
(Fig. 2B). A previous report has demonstrated the lack of correla-
tion between HBV mRNA/protein levels and virion secretion
(Kalinina et al., 2003). In addition, other factors such as nucleo-
capsids with ss-DNA or RNA may also have a negative impact on
virion secretion (Ning et al., 2011). Previous studies investigating
virion secretion between the wild-type and the G1896A mutant
found no differences (Tong et al., 1992; Chen et al., 2003; Jammeh
et al., 2008). Nonetheless, studies on virion morphogenesis of the
G1896A mutant are lacking; further studies in this area may help
us better understand the replication characteristics of this mutant.
Trans-complementation of HBeAg reduces the replication-ﬁtness and
transcription efﬁciency of the G1896A-HBV
Having demonstrated higher replication ﬁtness and transcrip-
tion efﬁciency for the G1896A-HBV we sought to understand the
underlying mechanism by trans-complementation of HBeAg. We
speculate two possible reasons for this: (a) Stabilization of the stem-
loop structure present in both HBV-pg-RNA and HBV pre-core RNA
through T:A base-pairing between nucleotides 1858 and 1896 (a
result of the G1896A mutation that replaces the T:G wobble base-
pairing between the 1858 and 1896 nucleotides) may result in
enhanced RNA expression. Previous studies on prokaryotic and
eukaryotic mRNA have demonstrated the link between the stability
of the stem-loop structure and mRNA expression (Gold, 1988; de
Smit and van Duin,1994; Tessier et al., 1984) (b) The presence of
HBeAg inhibits the replication ﬁtness and transcription efﬁciency of
the wt-HBV than that of the G1896A-HBV. We found that the latter
mechanism is likely to be true as trans-complementation of HBeAg
(encoded by pCMVHBeAg) inhibited the replication ﬁtness and
transcription efﬁciency of the G1896A-HBV in our study (Fig. 3).
To the best of our knowledge this is the ﬁrst time that the presence
of HBeAg has been linked to inhibition of replication ﬁtness and
transcription efﬁciency of the G1896A mutant.
Majority of HBeAg positive patients have mixed infection with the
1896-wild-type and the G1896A mutant (Chu et al., 2002). Differences
in the dynamics of HBV replication in hepatocytes with mixed
infection (1896-wild-type and G1896A mutant) than hepatocytes
infected exclusively with the G1896A mutant strains (without the
1896-wild-type strains) have not been previously recognized. Our
ﬁnding of HBeAg-mediated inhibition of the G1896A mutant suggests
that the replication of this mutant may be signiﬁcantly attenuated by
the presence of HBeAg-expressing strains within the same hepatocyte.
Although transient over-expression of HBeAg along with an
HBeAg-expressing full-length construct has been studied pre-
viously (Scaglioni et al., 1997a; Lamberts et al., 1993), to our
knowledge the role of trans-complementation of HBeAg with
strains lacking HBeAg expression has not been studied. Our
ﬁndings imply that higher replication ﬁtness and transcription
efﬁciency of the G1896A-HBV is primarily linked to the loss of
HBeAg rather than RNA stem-loop stabilization by T:A base-
pairing (between nucleotide positions 1858 and 1896).
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Fig. 3. Expression of HBeAg inhibits replication of the G1896A mutant. (A)Huh7 cells transfected with G1896A-HBV in combination with HBeAg-expressing plasmid
(pCMVHBeAg) showed lower replication ﬁtness (pg-RNA/cccDNA) than G1896A-HBV co-transfected with pCMVG189GA(P¼0.03). (B) Similarly, G1896A-HBV when
complemented in-trans with HBeAg showed lower transcription efﬁciency than G1896A-HBV co-transfected with pCMVG189GA (Po0.005). (C) HBsAg levels (OD values
at 450 nm) in culture supernatant of cells transfected with HBV constructs: G1896A-HBV co-transfected with pCMVHBeAg showed no signiﬁcant difference in HBsAg levels
than that of G1896A-HBV co-transfected with pCMVG189GA (P40.05).
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Trans-complementation of the G1896A mutant with HBeAg
(pCMVHBeAg) marginally lowered secreted HBsAg levels than that
in the supernatant from cells transfected with the G1896A mutant
and pCMVG1896A; however this difference was not statistically
signiﬁcant (Fig. 3C).
In summary, our data shows that G1896A mutation, the most
clinically relevant and frequently observed mutation in the pre-
core region, which abrogates HBeAg production, confers a high
replication phenotype to the virus. Though previous reports have
demonstrated a high replication phenotype for the precore
(G1896A) HBV mutant using in vitro cell culture models, our study
differs from earlier reports as we used a unit-length HBV construct
and the corresponding G1896A mutant construct, both without
heterologous promoters. Importantly, we demonstrate higher
replication ﬁtness (pg-RNA/ccc) and transcription efﬁciency (pre-
core RNA/ccc) of the G1896A mutant. Differences between the
wild-type and the G1896A mutant in the early stages of HBV
replication (HBV pg-RNA and HBV pre-core RNA synthesis)have
not been recognized previously. In addition, our trans-
complementation experiments clearly demonstrate that differ-
ences in the replication characteristics between the wild-type
HBV and G1896A mutant is attributable to the loss of HBeAg rather
than the stability of stem-loop structure in the HBV pre-genome.
Taken together, our ﬁndings highlight the role of previously
unrecognized mechanisms for the high-replicating phenotype
observed for the G1896A mutant in vitro. We believe that these
results provide a novel perspective on our current understanding
of the G1896A mutant and the perceived role of HBeAg in
regulating HBV replication.
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